Jump to content
Powered by

Red biotechnology

The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberg

  • Press release - 30/09/2015

    Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug products, the company will invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period. As a leading contract development and manufacturing organization, Vetter is continuously developing its manufacturing sites and techniques to prepare them for future needs and…

  • Article - 31/08/2015

    Dr. Günter Roth is head of the “Microarray Copying“ research group at the Center for Biological Systems Analysis (ZBSA) at the University of Freiburg. Roth, who studied physics and biochemistry, has developed a biomolecule copier that he plans to use to establish his own company. The company will be called BioCopy, and the planned product lines, AptaSWIFT and immune2day, have already won numerous prizes for Roth and his team. In an interview with…

  • Article - 24/08/2015

    Manual work is out – the rapid production of cells that carry foreign genetic material for use in research and industry can only be achieved with a high degree of automation. A fully automated process is needed to cultivate, analyse and select the cells. One such automated system has been developed by the Fraunhofer Society and the Max Planck Society in a collaborative project called Autranomics.

  • Article - 17/08/2015

    Sartorius Stedim Biotech (SSB), a leading international supplier to the pharmaceutical and biotechnology industries, acquired Laupheim-based Cellca GmbH on 1st July 2015. Walter Pytlik talked to Cellca CEO Hugo de Wit, who has been at the helm of the company since 2010, the first two years jointly with Dr. Aziz Cayli, about the background to the change of ownership and the consequences it will have.

  • Article - 18/05/2015

    Parvoviruses such as H-1PV have been shown to selectively attack and destroy human cancer cells. However, they are unable to replicate in healthy human cells. A preliminary clinical trial is currently being carried out to assess the suitability of parvoviruses for treating malignant brain cancer. Scientists from the German Cancer Research Center (DKFZ) have now discovered the cause of the selective effect of H-1PV. The finding helps identify…

  • Dossier - 13/04/2015

    The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.

  • Article - 23/03/2015

    cytena GmbH, a start-up company which was spun out from the Department of Microscystems Engineering (IMTEK) at the University of Freiburg in 2014, has developed a device that enables single cells to be deposited safely and gently using a single-cell printer called cy-Clone. Once processed, the cells can be used to study tumour heterogeneity and to create clonal cell lines for producing antibodies.

  • Article - 23/03/2015

    Crowdfunding has become a popular widely-talked-about financing tool that opens up new ways of acquiring money for projects that might not otherwise receive backing. The financing model is based on the simple idea of raising many small amounts of capital to finance a large project. In early 2015 a company called Riboxx secured the capital it needed through a campaign on the Seedmatch crowdfunding platform. The German company aescuvest GmbH…

  • Article - 16/03/2015

    Microbial metabolic products can be used in the fight against dangerous pathogens such as multidrug-resistant bacteria. Since summer 2014, microbiologist Prof. Dr. Heike Brötz-Oesterhelt has been investigating the mechanisms of action of bacterial substances at the University of Tübingen with the aim of paving the way for new antibiotics. Interesting candidates have already been identified.

  • Article - 09/03/2015

    Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer.

  • Press release - 07/03/2015

    Thorough examination of the genome of cancer cells is essential for a better understanding of the disease and to improve treatment. Therefore, the German Cancer Research Center (DKFZ), with the support of the German Cancer Consortium (DKTK), will invest in the Illumina HiSeq X Ten Sequencing System, the world’s first and only platform to deliver full coverage human whole genome for less than 1000 Euros per genome with the power to sequence more…

  • Press release - 06/03/2015

    The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest €46 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA platform. In addition, CureVac’s…

Website address: https://www.gesundheitsindustrie-bw.de/en/article/biotech